Educational scope notice: This is a study note for medical students, not medical advice, diagnosis, or treatment guidance. Clinical management should follow local protocols and current guidelines.
ALS looks different depending on which motor neurons fail first. Six phenotypes describe that spectrum. Phenotype predicts pace, so recognising the pattern guides prognosis and planning.
The six phenotypes
Figures below are cohort approximations. Individual courses vary widely.
| Phenotype | Key feature | Typical prognosis |
|---|---|---|
| Classical ALS | Combined UMN and LMN signs across multiple segments | Around 3–4 years from first symptoms; about 1 in 10 live 10 years or more |
| Progressive bulbar palsy | Speech and swallowing fail first, with dysarthria usually preceding dysphagia | Variable; often spreads to generalised ALS with shorter survival |
| LMN-predominant disease, including progressive muscular atrophy | LMN signs only at onset | Slower on average than classical ALS |
| Primary lateral sclerosis | UMN signs only: spasticity and hyperreflexia | Markedly slow; often a decade or more, with near-normal lifespan in many series |
| Flail-arm syndrome | LMN weakness largely confined to the arms | Median around 5–6 years, roughly double classical ALS |
| Flail-leg syndrome | LMN weakness largely confined to the legs | Median around 5–6 years, with a majority alive at 5 years |
Primary lateral sclerosis is rare, confidently demarcated in under 3% of motor neuron disease. Flail phenotypes progress roughly twice as slowly as classical ALS but do not carry the near-normal course sometimes claimed for them.
How the disease starts
First symptoms fall roughly into thirds. Some patients notice foot drop or gait disturbance. Others lose hand dexterity. A third group starts with dysarthria or dysphagia.
Respiratory onset and isolated neck flexor weakness are uncommon. Bulbar onset is relatively more common in older women.
One bedside heuristic compares bulbar ALS with myasthenia gravis. In bulbar ALS, dysarthria usually precedes dysphagia. In myasthenia, dysphagia often comes first, reflecting fatigable transmission rather than neuron loss. This contrast is a heuristic, not a rule.
Staging the course
Two systems stage progression. King’s staging counts anatomical spread: one region, then two, then three. Stage 4 marks nutritional (4A) or respiratory (4B) failure. Stage 5 is death.
MITOS tracks loss of independence across four functions: movement, swallowing, communication, and breathing. It draws on ALS Functional Rating Scale scores.
What modifies prognosis
Non-invasive ventilation and timely nutritional support extend survival. Executive dysfunction predicts shorter survival, plausibly because it complicates decisions about gastrostomy and ventilation.
Evidence anchors
- NICE. Motor neurone disease: assessment and management (NG42): https://www.nice.org.uk/guidance/ng42
- National Institute of Neurological Disorders and Stroke. Amyotrophic lateral sclerosis: https://www.ninds.nih.gov/health-information/disorders/amyotrophic-lateral-sclerosis-als
- Geevasinga N et al. Diagnosing ALS: the Gold Coast criteria and the role of EMG (2022, open access): https://pmc.ncbi.nlm.nih.gov/articles/PMC9120398/
- Flail-arm and flail-leg syndromes: natural-history cohorts (open access): https://pmc.ncbi.nlm.nih.gov/articles/PMC2821838/
- King’s and MITOS staging in ALS (JNNP): https://jnnp.bmj.com/content/92/2/165